| Exceed Physical Therapy Of Biloxi | |
|
920 Cedar Lake Rd Ste S, Biloxi, MS 39532-2107 | |
| (228) 324-9145 | |
| Not Available |
| Full Name | Exceed Physical Therapy Of Biloxi |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 920 Cedar Lake Rd Ste S, Biloxi, Mississippi |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023895398 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| Provider Name | Todd M Smith |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1851407670 PECOS PAC ID: 5395045108 Enrollment ID: I20160211001367 |
News Archive
Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug.
The WHO Fracture Risk Assessment Tool (FRAX-) has today been launched in version 3.1., featuring eight new country models and accessible in six additional languages.
An international study led by a Johns Hopkins pulmonary expert finds that the drug tiotropium (marketed as the Spiriva brand), can be delivered safely and effectively to people with chronic obstructive pulmonary disease (COPD) in both "mist" and traditional "dry powder" inhalers.
› Verified 1 days ago
| Provider Name | Rachael Hines |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1407304801 PECOS PAC ID: 1759664337 Enrollment ID: I20170206000307 |
News Archive
Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug.
The WHO Fracture Risk Assessment Tool (FRAX-) has today been launched in version 3.1., featuring eight new country models and accessible in six additional languages.
An international study led by a Johns Hopkins pulmonary expert finds that the drug tiotropium (marketed as the Spiriva brand), can be delivered safely and effectively to people with chronic obstructive pulmonary disease (COPD) in both "mist" and traditional "dry powder" inhalers.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Exceed Physical Therapy Of Biloxi 12261 Highway 49 Ste 1, Gulfport, MS 39503-2976 Ph: (228) 218-4820 | Exceed Physical Therapy Of Biloxi 920 Cedar Lake Rd Ste S, Biloxi, MS 39532-2107 Ph: (228) 324-9145 |
News Archive
Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug.
The WHO Fracture Risk Assessment Tool (FRAX-) has today been launched in version 3.1., featuring eight new country models and accessible in six additional languages.
An international study led by a Johns Hopkins pulmonary expert finds that the drug tiotropium (marketed as the Spiriva brand), can be delivered safely and effectively to people with chronic obstructive pulmonary disease (COPD) in both "mist" and traditional "dry powder" inhalers.
› Verified 1 days ago
Dr. Joseph Camoratto, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 301 Fisher St, Biloxi, MS 39534 Phone: 228-376-5231 | |
Mr. Eric Matalubos Raneses, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 251 Eisenhower Dr Apt 394, Biloxi, MS 39531 Phone: 228-313-4724 | |
Mr. Rodney Keith Ganey, P.T., A.T.C Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1990 Popps Ferry Rd, Biloxi, MS 39532 Phone: 228-385-9000 | |
Alisha Farrish, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1720a Medical Park Dr, Suite 210, Biloxi, MS 39532 Phone: 228-392-9355 Fax: 228-392-5288 | |
Kayla Ann Todd, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1720a Medical Park Dr Ste 210, Biloxi, MS 39532 Phone: 228-230-2663 Fax: 228-546-3257 | |
Lauren Breland, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2541 Pass Rd Ste F, Biloxi, MS 39531 Phone: 228-388-1002 Fax: 228-388-1006 |